NCT05370079Recruiting
Control Cohort CTRL COH
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- First submitted
- 6 May 2022
- Start date
- 8 Aug 2023
- Primary completion date
- 8 Aug 2028
- Lead sponsor
- Hospices Civils de Lyon
- NCT number
- NCT05370079
What you commit to
- Study type: Interventional
- Planned participants: 350
- From 8 Aug 2023 to the primary completion date, 8 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
Other
- refusal consent
- patient under guardianship
Who the study is looking for
- patient with consent
- patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospices Civils de Lyon Coordinator of this site? Confirm its status | Bron | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.